A shorter window and a sharper edge for digital trust

Tern plc

The shifting ground beneath certificate management has rarely felt so immediate. With Apple’s move to limit public TLS certificate lifespans to just 47 days, and industry momentum suggesting others like Google are not far behind, the once-comfortable cycle of annual renewal is vanishing. What replaces it is not simply a more frequent cadence, but an entirely different mindset, one in which automation becomes not just a competitive advantage but an operational necessity.

For organisations still reliant on manual certificate management, this policy change is not a minor update, it’s an existential challenge. The former 398-day window allowed room for error, grace periods, and human processes. The new 47-day limit compresses all of that. Enterprises will now face nearly eight times as many renewal cycles in the same timeframe, and each one carries the risk of downtime or security lapse if handled incorrectly. The pace alone would break most conventional IT workflows, let alone those already strained by hybrid infrastructure, sprawling device fleets, and growing regulatory oversight.

The pressure is acute in Internet of Things (IoT) environments, where sheer scale meets unique constraints. Devices often sit behind firewalls or connect intermittently, while their hardware and firmware may not support traditional update paths. The idea of rotating certificates manually across tens of thousands, or even millions, of devices every six weeks is clearly unworkable. And yet, that’s now the bar for compliance, continuity, and security assurance.

Against this backdrop, the case for automation writes itself. But the reality is more nuanced than simply plugging in a software tool. Automation must be policy-aware, lifecycle-aware, and above all identity-centric. That’s where Device Authority has carved out its place. Rather than adapting legacy PKI tools to fit the IoT challenge, the company has built a purpose-designed framework that recognises identity as foundational. Every certificate, every rotation, every revocation is tied to a specific, verifiable device identity, managed at scale, in real time.

This approach removes the margin for human error and introduces a new kind of resilience. Devices can be onboarded securely with zero-touch provisioning. Certificates can be issued, rotated, and retired according to predefined security policies without the need for constant oversight. And every action is logged and auditable, aligning with evolving regulatory demands and internal governance frameworks. It’s a system built not only for compliance, but for agility in the face of ever-tightening operational tolerances.

Importantly, this model is not just about meeting today’s requirements, it’s about anticipating tomorrow’s. The shortening of certificate lifespans is part of a broader shift towards zero trust architectures, continuous validation, and real-time threat response. Organisations that treat automation as a long-term strategy rather than a short-term fix will find themselves far better equipped as the landscape continues to evolve.

Device Authority’s positioning here is compelling. It does not sell simplicity for the sake of convenience; it delivers sophistication that aligns directly with the structural needs of complex, high-scale environments. By focusing on identity-driven automation, it sidesteps the limitations of legacy tools and addresses the specific pain points that are now coming sharply into focus. This is not just about avoiding outages—it’s about enabling a more dynamic, trust-centric infrastructure that can adapt as fast as the policies around it change.

In a world where the trust window is closing faster than ever, the companies that will thrive are those that treat automation as infrastructure, not overhead. The reduction in TLS certificate validity is not an isolated event, it’s a signal. And Device Authority has not just heard it; it has been building for it.

Device Authority provides automated identity and access management for connected devices, with a strong focus on PKI and secure onboarding for IoT environments. Its solutions help enterprises deploy scalable, secure, and policy-compliant infrastructure in a digital-first world.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search